These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17928746)

  • 61. [[Antithrombin III concentrates in the treatmetn of sepsis and septic shock: indictions, limits and future prospects] ].
    Baudo F; de Cataldo F
    Minerva Anestesiol; 2000 Nov; 66(11 Suppl 1):3-23. PubMed ID: 11213542
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Redox mechanisms of vascular cell dysfunction in sepsis.
    Azevedo LC; Janiszewski M; Soriano FG; Laurindo FR
    Endocr Metab Immune Disord Drug Targets; 2006 Jun; 6(2):159-64. PubMed ID: 16787290
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The pathogenesis of septic shock.
    Crowley SR
    Heart Lung; 1996; 25(2):124-34; quiz 135-6. PubMed ID: 8682683
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Is a different view on the pathophysiology of sepsis the key for novel therapeutic options?].
    Schlegel N; Flemming S; Meir M; Germer CT
    Chirurg; 2014 Aug; 85(8):714-9. PubMed ID: 25103839
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Elevated biomarkers of endothelial dysfunction/activation at ICU admission are associated with sepsis development.
    Vassiliou AG; Mastora Z; Orfanos SE; Jahaj E; Maniatis NA; Koutsoukou A; Armaganidis A; Kotanidou A
    Cytokine; 2014 Oct; 69(2):240-7. PubMed ID: 25016133
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Endothelial dysfunction: a therapeutic target in bacterial sepsis?
    Vincent JL; Ince C; Pickkers P
    Expert Opin Ther Targets; 2021 Sep; 25(9):733-748. PubMed ID: 34602020
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Marked regional endothelial dysfunction in mottled skin area in patients with severe infections.
    Bourcier S; Joffre J; Dubée V; Preda G; Baudel JL; Bigé N; Leblanc G; Levy BI; Guidet B; Maury E; Ait-Oufella H
    Crit Care; 2017 Jun; 21(1):155. PubMed ID: 28641580
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment With Human Wharton's Jelly-Derived Mesenchymal Stem Cells Attenuates Sepsis-Induced Kidney Injury, Liver Injury, and Endothelial Dysfunction.
    Cóndor JM; Rodrigues CE; Sousa Moreira Rd; Canale D; Volpini RA; Shimizu MH; Camara NO; Noronha Ide L; Andrade L
    Stem Cells Transl Med; 2016 Aug; 5(8):1048-57. PubMed ID: 27280799
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Myocardial dysfunction in sepsis: mechanisms and therapeutic implications.
    Price S; Anning PB; Mitchell JA; Evans TW
    Eur Heart J; 1999 May; 20(10):715-24. PubMed ID: 10329063
    [No Abstract]   [Full Text] [Related]  

  • 70. Antioxidant therapy in critical care--is the microcirculation the primary target?
    Biesalski HK; McGregor GP
    Crit Care Med; 2007 Sep; 35(9 Suppl):S577-83. PubMed ID: 17713412
    [TBL] [Abstract][Full Text] [Related]  

  • 71. ARF6 inhibition stabilizes the vasculature and enhances survival during endotoxic shock.
    Davis CT; Zhu W; Gibson CC; Bowman-Kirigin JA; Sorensen L; Ling J; Sun H; Navankasattusas S; Li DY
    J Immunol; 2014 Jun; 192(12):6045-52. PubMed ID: 24835390
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The role of biomarkers of endothelial activation in predicting morbidity and mortality in patients with severe sepsis and septic shock in intensive care: A prospective observational study.
    Fang Y; Li C; Shao R; Yu H; Zhang Q
    Thromb Res; 2018 Nov; 171():149-154. PubMed ID: 30312800
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Infection and septic shock. Pathophysiology (microcirculation and the clinical picture)].
    Schuster HP
    Verh Dtsch Ges Inn Med; 1987; 93():336-43. PubMed ID: 3327289
    [No Abstract]   [Full Text] [Related]  

  • 74. [Causes and therapy of organ failure: mediators, their role and therapeutic implications as exemplified by the infected patient].
    Neuhof H
    Langenbecks Arch Chir; 1987; 372():43-7. PubMed ID: 3123823
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The microcirculation in sepsis.
    Tyagi A; Sethi AK; Girotra G; Mohta M
    Indian J Anaesth; 2009 Jun; 53(3):281-93. PubMed ID: 20640135
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Promotion of vascular integrity in sepsis through modulation of bioactive adrenomedullin and dipeptidyl peptidase 3.
    van Lier D; Kox M; Pickkers P
    J Intern Med; 2021 Jun; 289(6):792-806. PubMed ID: 33381880
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Genetic insights into sepsis: what have we learned and how will it help?
    Wurfel MM
    Curr Pharm Des; 2008; 14(19):1900-11. PubMed ID: 18691101
    [TBL] [Abstract][Full Text] [Related]  

  • 78. New paradigms in sepsis: from prevention to protection of failing microcirculation.
    Hawiger J; Veach RA; Zienkiewicz J
    J Thromb Haemost; 2015 Oct; 13(10):1743-56. PubMed ID: 26190521
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Endothelial ROS and Impaired Myocardial Oxygen Consumption in Sepsis-induced Cardiac Dysfunction.
    Potz BA; Sellke FW; Abid MR
    J Intensive Crit Care; 2016; 2(1):. PubMed ID: 27135058
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Progressive endothelial cell damage in correlation with sepsis severity. Defibrotide as a contender.
    Fernández S; Palomo M; Molina P; Díaz-Ricart M; Escolar G; Téllez A; Seguí F; Ventosa H; Torramade-Moix S; Rovira M; Carreras E; Nicolás JM; Castro P
    J Thromb Haemost; 2021 Aug; 19(8):1948-1958. PubMed ID: 33872468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.